Recorded fact · drug.trial_access

drug.trial_access for semaglutide

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact baa5cb4f resolves to.

The record

Fact id	`baa5cb4f378eec5ac335abd6`
Entity	drug: semaglutide
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "SEMAGLUTIDE",
 "recruitingInterventionalCount": 154,
 "notYetRecruitingCount": 88,
 "byPhase": {
  "PHASE1/PHASE2": 5,
  "PHASE3": 32,
  "PHASE2": 29,
  "PHASE1": 15,
  "PHASE2/PHASE3": 6,
  "PHASE4": 37,
  "NA": 28,
  "EARLY_PHASE1": 2
 },
 "trials": [
  {
   "nctId": "NCT07651319",
   "briefTitle": "Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "The Methodist Hospital Research Institute",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2026-09-01",
   "conditions": [
    "Alzheimer Dementia (AD)"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07651319"
  },
  {
   "nctId": "NCT07866066",
   "briefTitle": "Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Amgen",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2026-10-16",
   "conditions": [
    "Diabetes Mellitus, Type 2"
   ],
   "countries": [
    "United States",
    "Canada"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07866066"
  },
  {
   "nctId": "NCT07845500",
   "briefTitle": "A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Pfizer",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2026-09-30",
   "conditions": [
    "Obesity",
    "Overweight and/or Obesity",
    "Overweight"
   ],
   "countries": [
    "United States",
    "Australia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07845500"
  },
  {
   "nctId": "NCT06897475",
   "briefTitle": "A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Eli Lilly and Company",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2025-03-28",
   "conditions": [
    "Type 2 Diabetes"
   ],
   "countries": [
    "United States",
    "Canada",
    "Germany",
    "Poland",
    "Puerto Rico",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06897475"
  },
  {
   "nctId": "NCT07772960",
   "briefTitle": "Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Yale University",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2026-10-01",
   "conditions": [
    "Alcohol Use Disorder (AUD)",
    "Obesity (BMI Equal to or >30)"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07772960"
  },
  {
   "nctId": "NCT06975111",
   "briefTitle": "Focusing on the Menopausal Transition to Improve Mid-Life Women's Health",
   "phase": [
    "PHASE2",
    "PHASE3"
   ],
   "leadSponsor": "University of Colorado, Denver",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2026-03-01",
   "conditions": [
    "Menopause",
    "Menopause Hot Flashes",
    "Menopause Related Conditions"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06975111"
  },
  {
   "nctId": "NCT07840729",
   "briefTitle": "Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Shanghai JMT-Bio Inc.",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-02",
   "startDate": "2026-10-20",
   "conditions": [
    "Valid MeSH Conditiongs"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07840729"
  },
  {
   "nctId": "NCT07872904",
   "briefTitle": "FutureShape Family",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Signe Torekov",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-29",
   "startDate": "2026-10-01",
   "conditions": [
    "Obesity",
    "Overweight"
   ],
   "countries": [
    "Denmark"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07872904"
  },
  {
   "nctId": "NCT07900438",
   "briefTitle": "A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Novo Nordisk A/S",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-28",
   "startDate": "2026-10-12",
   "conditions": [
    "Cardiovascular Risk",
    "Chronic Kidney Disease"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07900438"
  },
  {
   "nctId": "NCT07900074",
   "briefTitle": "Mechanisms of Weight Loss: Tirzepatide vs Semaglutide",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "McMaster University",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-28",
   "startDate": "2026-10-31",
   "conditions": [
    "Obesity (Disorder)"
   ],
   "countries": [
    "Canada"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07900074"
  },
  {
   "nctId": "NCT03884075",
   "briefTitle": "Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-27",
   "startDate": "2019-07-24",
   "conditions": [
    "Non-Alcoholic Steatohepatitis",
    "Non-Alcoholic Fatty Liver Disease"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT03884075"
  },
  {
   "nctId": "NCT07592546",
   "briefTitle": "Translational Health Resea
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: f42420bf07fbd3a481aceb10bcf337b9bc680275f5f1a5016c3a8fe61865210f.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.